Ustekinumab Versus Anti-tumour Necrosis Factor Alpha Agents as Second-Line Biologics in Crohn's Disease.

Eriksson, Carl; Söderling, Jonas; Karlqvist, Sara; Bröms, Gabriella; Everhov, Åsa H; Bergemalm, Daniel; Ludvigsson, Jonas F; Olén, Ola; Halfvarson, Jonas

Eriksson, Carl; Söderling, Jonas; Karlqvist, Sara; Bröms, Gabriella; Everhov, Åsa H; Bergemalm, Daniel; Ludvigsson, Jonas F; Olén, Ola; Halfvarson, Jonas.

Afiliação

Eriksson C; Department of Gastroenterology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden. carl.eriksson@regionorebrolan.se.
Söderling J; Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden. carl.eriksson@regionorebrolan.se.
Karlqvist S; Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
Bröms G; Department of Gastroenterology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
Everhov ÅH; Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
Bergemalm D; Division of Gastroenterology, Department of Specialist Medicine, Danderyd Hospital, Stockholm, Sweden.
Ludvigsson JF; Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
Olén O; Department of Clinical Science and Education Södersjukhuset, Karolinska Institutet, Stockholm, Sweden.
Halfvarson J; Department of Gastroenterology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.

Dig Dis Sci ; 68(7): 3119-3128, 2023 07.

Article em En | MEDLINE | ID: mdl-36929241

Assuntos

Produtos Biológicos; Doença de Crohn; Humanos; Ustekinumab/efeitos adversos; Doença de Crohn/patologia; Fator de Necrose Tumoral alfa; Inibidores do Fator de Necrose Tumoral/efeitos adversos; Anticorpos Monoclonais Humanizados/efeitos adversos; Adalimumab/efeitos adversos; Infliximab/efeitos adversos; Fatores Biológicos/uso terapêutico; Produtos Biológicos/efeitos adversos; Necrose; Resultado do Tratamento

Palavras-chave

Anti-TNF; Comparative effectiveness; Comparative safety; Crohn's disease; Population-based study; Ustekinumab

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Produtos Biológicos / Doença de Crohn Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Dig Dis Sci Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Suécia

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google